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What is the most appropriate treatment for chronic rhinosinusitis?  
Abstract 
Chronic rhinosinusitis (CRS) is a common, treatable disease that affects approximately 11% 
of British adults. It places an enormous burden on patients, with significant detriment to their 
quality of life, and the health service as it consumes vast numbers of both primary and 
secondary care resources. However, there is considerable variability in treatment strategies 
and prescribing practices. This review summarises the key recommendations from landmark 
guidelines in the treatment of CRS and critically appraises the evidence for treatment. 
Main messages: 
 Chronic rhinosinusitis is a common disease in UK adults and causes significant 
detriment to life 
 The best evidence for effective treatment is for topical intranasal corticosteroids and 
saline irrigation 
 For patients who do not respond to this first line treatment, there are many potential 
avenues for further treatment but there is controversy about which strategy is the 
most effective 
Chronic rhinosinusitis (CRS) is defined as inflammation of the mucosal lining of the nasal 
cavity and paranasal sinuses that has been present for more than three months; causing 
characteristic symptoms such as nasal blockage, discharge, reduction or loss of smell 
sensation, and facial pressure. It is a broad clinical description that encompasses several 
phenotypes, most often divided into CRS with polyps and CRS without polyps. CRS may be 
the end point of several different inflammatory pathways and may be secondary to specific 
conditions such as cystic fibrosis or fungal aetiology, but most often cannot be attributed to a 
single pathophysiological trigger.  
 
CRS places an enormous burden upon both physicians and its sufferers. It is common 
amongst the general population, affecting approximately 11% of UK adults [1], and causes 
greater detriment to quality of life (QoL) than angina or chronic lower respiratory tract disease 
[2]. Not only is it a quality of life issue, CRS patients frequently have comorbid asthma, and 
poorly controlled CRS is associated with more frequent asthma exacerbations and a need for 
hospitalisation. The socio-economic cost of CRS is significant with 57% of patients reporting 
absenteeism and 28% experiencing associated anxiety and depression [3] [4]. One percent of 
all UK adults will visit their GP with CRS symptoms each year and require an average of 4 
appointments each year; despite this, one in three patients in primary care have poorly 
controlled symptoms[5]. CRS that cannot be adequately managed in primary care may require 
referral to secondary care, and data from Hospital Episode Statistics shows that in a single 
year there were approximately 120,000 outpatient consultations for CRS and 40,000 sinus 
operations performed in England and Wales[6]. However, there remains considerable debate 
regarding optimum management strategies leading to wide variation in practice [7]. 
 
Treatment evidence and guidelines 
 
The touchstone for treatment of CRS is The European Position Paper on Rhinosinusitis and 
Nasal Polyps published in 2012 (EPOS 2012) [8]. EPOS 2012 syntheses the best available 
evidence and expert opinion into easy to follow treatment flowcharts for both primary care 
physicians and ENT specialists, but acknowledges the large gaps in high quality trial data 
upon which to base their guidance. In the intervening 7 years since EPOS was published, the 
International Consensus Statement on Allergy and Rhinology (ICAR) [9] was agreed by a 
multinational working group who undertook a comprehensive overview of the literature. The 
working group graded the available evidence and used it as the basis for recommendations; 
where no evidence was available no recommendation was made. ICAR is therefore an 
exhaustive insight into the current state of the science in CRS and an invaluable tool for the 
otolaryngology community; for primary care however the EPOS 2012 remains perhaps the 
more accessible guide. In addition there have also been several Cochrane reviews [10-16] of 
treatments available for CRS, and these reviews along with the  international consensus 
guidelines have been used to synthesise a NICE clinical knowledge summary, most recently 
updated in 2018 [17]. 
 
Intranasal treatment 
The foundation of CRS treatment is regular use of intranasal saline irrigation and 
corticosteroids and this strategy finds unanimous favour amongst the guidelines mentioned 
above. The evidence is weak but consistent: a Cochrane systematic review studied the effects 
of saline irrigation in people with chronic sinusitis [12]. This identified only two studies that 
could robustly be included - one which compared the effect of high volume hypertonic saline 
irrigation to placebo in CRS patients both with and without polyps, and another which studied 
only patients with polyps and compared the use of nasal saline irrigation. This Cochrane 
review concluded that there was weak evidence from these trials to support the use of nasal 
saline irrigation. In addition, it is a low-cost treatment which with low risk of adverse events. 
For this reason, it is recommended for virtually all patients with CRS although in practice is 
usually used in combination with other therapies. 
Intranasal corticosteroids are similarly favoured by all expert guidelines. There is a greater 
number of trials upon which to base this opinion. A Cochrane systematic review [11] identified 
(search date August 2015) 18 randomised controlled trials (RCTs) which studied the use of 
intranasal steroids versus placebo in CRS. The majority of these studies included patients with 
nasal polyps. Regular intranasal corticosteroid use was reported to be superior to placebo in 
all reported symptoms, although there was no evidence to support an overall improvement in 
quality of life. A further Cochrane review of the different formulations of intranasal 
corticosteroids and methods of delivery [13] did not identify any single agent with convincing 
evidence of superiority, however there is an advantage offered by the second generation 
agents (e.g. mometasone furoate, fluticasone propionate, fluticasone furoate) which have 
favourable pharmacokinetic characteristics that minimise systemic bioavailability (< 1%) 
compared with older intranasal corticosteroids (e.g. beclomethasone diproprionate, 
betamethasone). 
 
Oral corticosteroids 
Oral corticosteroids are commonly prescribed in the treatment of CRS although there is a 
distinct lack of evidence for their efficacy. The NICE CKS makes no reference to their use. A 
Cochrane review in 2016 [16] identified no studies of their use in CRS without polyps, a fact 
which is also reflected in the ICAR guideline [9]. Their use in patients with polyps is better 
established, with several studies demonstrating short term efficacy of oral corticosteroids in 
improving CRS related quality of life scores. Treatment courses are short – a typical regime 
might be 30mg per day of prednisolone for two to three weeks – and thus the risk of side 
effects such as adrenal suppression and loss of bone mass are minimal. However, there is a 
risk of side effects such as gastrointestinal disturbance and insomnia even with these short 
courses. Patients should also be warned of the risk of osteonecrosis – a risk which may occur 
at doses of steroid previously thought to be safe (lowest reported associated total dose 105mg, 
median associated dose 981mg) [18]. The benefit of oral corticosteroids typically last three to 
six months, and so are a reasonable choice for patients who have not improved on the first 
line of saline irrigation and topical corticosteroids. However, an evidence‐based risk analysis 
of oral corticosteroid use in CRS with polyps performed by Leung et al [19] demonstrated that 
risk exceeded benefit if used more frequently than once every two years. Oral corticosteroid 
use is therefore restricted to short, infrequent courses, and with full disclosure of the potential 
serious associated side effects for patients. 
 
Antibiotics 
Where there is consensus recommending the use of nasal douches and corticosteroids, there 
is controversy regarding the use of antibiotics. Antibiotics are one of the most commonly 
prescribed medicines for CRS: of the 1% of UK adults with CRS who visit their GP each year, 
91% of them will receive an antibiotic prescription [20]. They will often receive not just one but 
repeated courses of antibiotics [21]. There is pressure upon GPs to use antibiotics as a first 
line treatment, as recently some Clinical Commissioning Groups (CCGs) have insisted on a 3 
month trial of macrolide antibiotics prior to secondary care referral [22]. 
With the exception of acute infective exacerbations, routine use of antibiotics is controversial 
for three main reasons: firstly; the lack of high-quality evidence to support their efficacy; 
secondly, the emerging threat of antibiotic resistance; and thirdly, the side effects which may 
accompany some of the most commonly used agents. 
 
In 2016, the ICAR guideline noted a paucity of evidence for antibiotic use [9]; however, on 
balance it recommended that patients with polyps should not be prescribed short courses of 
non-macrolide antibiotics, unless in the particular circumstances of suffering an acute 
exacerbation. No conclusions could be drawn on longer courses, or for patients without polyps. 
This echoes the findings of a Cochrane review of the use of antibiotics in CRS, which found 
very little evidence that non-macrolide antibiotics are effective in patients with chronic 
rhinosinusitis although only two studies were fit for inclusion in analysis[15]. These 
recommendations guided the NICE Clinical Knowledge Summary [17] to make the 
recommendation to seek specialist advice before initiating long-term antibiotics in primary 
care.  
 
It is, however recognised that there does remain a role for appropriate use of macrolide 
antibiotics in specific circumstances. In particular there is growing interest in immune-
modulating and anti-inflammatory effects of macrolides in chronic airway inflammatory 
disease, with low-dose long term macrolides being prescribed for its effects on the immune 
response and not primarily as an anti-bacterial agent [23]. The Cochrane review of 2016 noted 
that there was a moderate quality of evidence of a modest improvement in disease‐specific 
quality of life in patients with chronic rhinosinusitis without nasal polyps receiving three months 
of a macrolide [15]. However, this improvement was short lived, as three months following the 
cessation of the antibiotics there was no measurable effect of treatment.   
 
Resistance 
Antibiotic resistance is considered one of the most significant threats to patients’ safety in 
Europe [24]. Evaluating effectiveness of antibiotics and promoting appropriate usage is 
integral to the UK 5-year antimicrobial resistance strategy [25] . Given the high prevalence of 
CRS and the variability in prescribing, overuse of inappropriate antibiotics may represent a 
public health danger through selective pressure on bacteria and resistance. In particular, 
macrolide resistance has been noted to have implications in infections secondary to 
Streptococcus pneumoniae (upper and lower respiratory tract infections) and Mycoplasma 
genitalium (sexually transmitted infections), leading to longer duration of illness and 
requirement for multiple antibiotic courses [26].  
 
Side effects 
Antibiotics are commonly associate with wide range of side effects ranging from the mild (rash, 
nausea, diarrhoea) to the life threatening (anaphylaxis). Specific to the use of macrolides are 
concerns about potential cardiovascular side-effects [27]. There have been a number of 
publications raising concerns about cardiac toxicity with erythromycin in patients with a 
prolonged QT interval [28, 29]. A 2016 study which looked at adverse outcomes associated 
with clarithromycin use found a significant association was found between clarithromycin use 
and cardiovascular mortality, where longer durations of clarithromycin use were associated 
with more cardiovascular events [29]. By contrast, this association was not found with use of 
β-lactam antibiotics leading the authors to hypothesise that it was an effect specific to 
clarithromycin. This hypothesis was unintentionally tested by the lead investigators of the 
CLARICOR trial who had planned to measure the efficacy of a two-week course of 500mg 
clarithromycin twice daily to improve the clinical manifestations of stable coronary heart 
disease [30]. The study was halted prematurely due to the finding of excess deaths in the 
intervention group: all-cause mortality was significantly higher in the group had taken 
clarithromycin, an effect which persisted for 10 years post intervention. The use of 
clarithromycin in patients with known cardiovascular disease is therefore only undertaken with 
a significant degree of caution.  
 
Surgery 
Patients who are referred to secondary care who are considered to have tried and failed 
appropriate medical therapy – which is to say, a sufficient trial of nasal douching and topical 
steroids - are considered candidates for endoscopic sinus surgery (ESS) [31, 32]. ESS is a 
loosely defined procedure and can range from very simple balloon expansion of the sinus 
openings, to extensive procedures that open every bony partition within the sinuses. The risks 
of surgery include epistaxis, breach of the skull base with resultant CSF leak or meningitis, 
and injury to the intraorbital structures which may result in impaired vision. Insufficient 
evidence to define the role and extent of surgery contributes to a 5-fold variation in UK 
intervention rates [33], with wide variation in surgical practice and very high rates of revision 
surgery [34] [35]. Such uncertainty resulted in inclusion of ESS in the NICE Database of 
Treatment Uncertainties (DUETS)[36].  
 
However, there can be no doubt that in appropriately selected patients, surgery offers 
significant and durable relief from symptoms. The largest UK study of CRS and its outcomes 
demonstrated that not only was there a significant improvement in patient reported symptoms 
following ESS, but that patients who had surgery earlier in their disease course had a greater 
degree of improvement that lasted longer versus those who underwent delayed surgery [37]. 
In addition to improving nasal symptoms, a systematic review demonstrated that ESS is 
associated with improved asthma control with significantly fewer attacks, hospitalisations, and 
a reduced requirement for medication use following sinus surgery in patients with comorbid 
CRS and asthma [38]. Each of the international consensus guidelines referenced above 
recommends that patients who have tried a course of appropriate medical therapy but do not 
have control of their symptoms should be considered as a candidate for surgery[8, 9].   
 
The path forwards 
In the last two decades the majority of new treatments that have become available for CRS 
have in the main been refinements rather than revolutions – for examples new formulations of 
intranasal steroids or third generation antihistamines. However, there are some genuinely new 
and exciting innovations which are on the cusp of integration to clinical practice. Monoclonal 
antibodies that bind to targets such as IgE, IL4, and IL5 were developed primarily as 
treatments for asthma, but clinical trials have demonstrated that several of these agents may 
also be effective in CRS with polyps [39]. At present they remain expensive and are limited to 
subsets of patients with difficult to treat asthma, but as prices fall in future and evidence for 
their efficacy accumulates then in future they may become available for the treatment of CRS. 
There have also been several promising avenues of research that may unlock further 
therapeutic targets, such as the role of the microbiome in sinus disease. However, as alluded 
to in the many international guidelines, there is a paucity of evidence for many of the 
treatments that are currently used in CRS before even considering new innovations. This has 
led to a redoubling of efforts in CRS research to produce high quality evidence for commonly 
available treatments. Key to these efforts are the need to accurately define the endotypes of 
disease which will be studied in trials, as broad clinical phenotypes such as “polyps” may 
encompass a wide range of underlying pathophysiology. Tightly defining the endotypes of 
disease for trial inclusion will permit robust examination of the response to treatment in each 
subgroup. Meta-analyses of CRS outcomes have been hampered by the broad clinical 
phenotypes, and using precise endotypes will enhance our ability to pool data from multiple 
trials; this will also be enabled by international consensus statements that define key criteria 
such appropriateness for ESS [40] and standardised sets of outcome measures [41]; and 
funding has been secured for one of the largest ever trials of interventions in CRS which will 
specifically examine the question of the efficacy of both macrolides and ESS (the MACRO trial 
[42]) in subgroups of patients defined by precise clinical and pathological parameters. At 
present, treatment of CRS exists in a time of genuine clinical equipoise where treatment is 
empirical and even international guidelines depend more heavily on expert opinion than robust 
scientific statements. Ongoing research endeavours aim to transform the treatment of CRS 
and usher in the era of precise, personalised medicine for these patients.  
  
Self Test Questions 
1) Which of the following are typical symptoms of chronic rhinosinusitis? 
a) Bleeding and crusting 
b) Unilateral blood tinged discharge 
c) Blockage, discharge, loss of sense of smell, facial pressure 
d) Visual disturbance 
Answer: c) these are typical CRS symptoms. Bleeding and crusting should raise the 
possibility of vasculitis, septal perforations, or recreational cocaine use. Unilateral blood 
tinged discharge is a red flag sign that should prompt concerns of malignancy. Visual 
disturbance may be caused by rare complications of CRS, but is not at all typical. 
 
2) The first line treatment for CRS is oral steroids and antibiotics. True or false? 
Answer: false. The first line treatment for CRS should be topical steroids and saline 
irrigation. 
 
3) A prolonged course of antibiotics (e.g. up to 3 months) may occasionally be used in 
specific circumstances. What group of antibiotics has the best evidence to support 
their use for prolonged courses in CRS? 
a) Penicillins 
b) Macrolides 
c) Aminoglycosides 
d) Fluoroquinolones 
Answer: Macrolides. 
 
4) And what adverse effects should the patient be advised of with these long term 
antibiotics? 
a) Cardiac comorbidity 
b) Osteonecrosis of the femoral head 
c) Epistaxis 
d) Infertility 
Answer: Cardiac comorbidity, particularly in patients with known heart disease. 
Osteonecrosis of the femoral head is a complication of oral steroids, while topical steroids 
may cause epistaxis. Macrolides are not recognised to cause infertility but their use should 
be restricted during pregnancy. The Food and Drug Administration of USA recommend that 
if a macrolide must be used in pregnancy then azithromycin is category B (i.e. safe in animal 
studies) while clarithromycin is category C (i.e. shown to cause harm in animal studies). 
5) There is good evidence to support the superiority of surgical treatment of CRS 
compared to medical treatment. True or false? 
Answer: false. There are very few high quality trials that compare medical treatment 
to surgery, and meta-analysis is made difficult by wide variability in study protocols.  
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